gefitinib mylan
mylan pharmaceuticals limited - gefitinib - carcinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - gefitinib mylan er angivet som monoterapi til behandling af voksne patienter med lokalt fremskreden eller metastatisk ikke‑småcellet lungekræft (nsclc) med aktiverende mutationer af egfr‑tk.
gefitinib "stada" 250 mg filmovertrukne tabletter
stada arzneimittel ag - gefitinib - filmovertrukne tabletter - 250 mg
gefitinib "teva" 250 mg filmovertrukne tabletter
teva b.v. - gefitinib - filmovertrukne tabletter - 250 mg
gefitinib "accord" 250 mg filmovertrukne tabletter
accord healthcare b.v. - gefitinib - filmovertrukne tabletter - 250 mg
gefitinib "glenmark" 250 mg filmovertrukne tabletter
glenmark arzneimittel gmbh - gefitinib - filmovertrukne tabletter - 250 mg
gefitinib "orion" 250 mg filmovertrukne tabletter
orion corporation - gefitinib - filmovertrukne tabletter - 250 mg
gefitinib "qilu" 250 mg filmovertrukne tabletter
qilu pharma spain s.l. - gefitinib - filmovertrukne tabletter - 250 mg
iressa
astrazeneca ab - gefitinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - iressa er indiceret til behandling af voksne patienter med lokalt fremskreden eller metastatisk ikke-small-cell lung cancer med aktiverende mutationer af epidermal-growth-factor-receptor tyrosin kinase.
zykadia
novartis europharm limited - ceritinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - zykadia er indiceret til behandling af voksne patienter med anaplastisk lymfom kinase (alk) positive avanceret ikke småcellet lungekræft (nsclc) tidligere behandlet med crizotinib.
lorviqua
pfizer europe ma eeig - lorlatinib - carcinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.